Scientists provide a comprehensive overview of the evolution and potential of TIL therapy. They describe its development and highlight its transformative potential. The recent U.S. Food and Drug ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, was approved in the United States on the basis of the pivotal C-144-01 study. A 5-year follow-up of the C-144-01 trial ...

Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s innovative TIL ...

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the ...

Richmond, Va.-based VCU Health’s Massey Comprehensive Cancer Center has become the first facility in Virginia to offer tumor-infiltrating lymphocyte therapy for advanced stage melanoma patients. TIL ...

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer ...

TAMPA, Fla. — The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant ...

Lymphedema Treatment Act: A Critical Step for Cancer Survivors, but Unresolved Equity Gaps Persist Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment ...